CClinicalTrials.gg
Not yet recruitingNCT07790289ASKUpdated Sep 3, 2026

Aerobic, Strength, Kegel (ASK) Exercise Intervention Perceptions for Postpartum Health

An interventional study of ASK Exercise Programme in Quality of Life, Body Composition and Sleep, sponsored by Chinese University of Hong Kong. Not yet recruiting at 1 site in Hong Kong. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The goal of this pilot clinical trial is to learn whether a 12-week home-based exercise programme is feasible, acceptable, and safe for postpartum women in Hong Kong who had hypertensive disorders of pregnancy. The exercise programme is called the Aerobic, Strength, and Kegel exercise programme, or ASK programme.

The main questions this study aims to answer are:

  • Can postpartum women follow the ASK exercise programme at home?
  • Is the ASK exercise programme acceptable and safe?
  • Does the ASK exercise programme show early benefits for postpartum recovery and health?

Researchers will compare women who receive the ASK exercise programme with women who receive standard postnatal care.

Participants will be randomly assigned to one of the two groups. They will complete study assessments at the beginning of the study and after 12 weeks. Women in the ASK exercise programme group will complete three 60-minute exercise sessions per week for 12 weeks, supported by a mobile app and wearable device. Women in the standard postnatal care group will continue to receive usual postnatal care.

Read the detailed description

This is a parallel-group pilot randomized controlled trial designed to evaluate the feasibility, acceptability, safety, and preliminary effectiveness of the ASK Programme, a 12-week home-based postpartum exercise intervention for Asian women in Hong Kong. The ASK Programme combines aerobic training, strength training, and Kegel-based pelvic floor muscle training, and is delivered through a study app with wearable-supported monitoring.

Eligible participants will be enrolled at 6 to 8 weeks postpartum and randomized in a 1:1 ratio to either the ASK Programme intervention group or the standard postnatal care control group. Participants in the intervention group will complete three home-based ASK exercise sessions per week for 12 weeks. Each session will include warm-up, aerobic training, strength training, pelvic floor muscle training, and cool-down. The control group will receive standard postnatal care.

Assessments will be conducted at baseline and within 1 week after completion of the 12-week intervention. The study will collect feasibility, adherence, safety, acceptability, clinical, behavioral, psychosocial, physiological, cardiometabolic, and exploratory biological data to inform the design of a future full-scale randomized controlled trial.

02

Conditions studied

  • Quality of Life
  • Body Composition
  • Sleep
  • Physical Abilities
  • Cardiometabolic Health
  • Postpartum Health

Keywords

  • Postpartum health
  • Postpartum exercise
  • Pelvic floor muscle training
  • Cardiometabolic health
  • Pilot randomized controlled trial
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Female Asian postpartum women aged 18 to 45 years
  • Singleton pregnancy
  • 6 to 8 weeks postpartum at the time of enrolment
  • Medically stable after childbirth
  • Physically able to participate in low-to-moderate intensity exercise training
  • Able and willing to participate in the 12-week study programme
  • Able to use the study app and wearable device, or willing to receive instruction on their use
  • Able to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Multiple pregnancy
  • Severe postpartum medical complications or conditions contraindicating exercise participation
  • Severe cardiovascular, respiratory, neurological, or major musculoskeletal conditions that may limit safe participation in exercise
  • Current use of medication likely to substantially affect cardiac function, including heart failure therapy
  • Antibiotic treatment within the preceding month
  • Severe mental illness or other condition affecting the ability to provide informed consent or comply with study procedures
  • Any medical, obstetric, or psychological condition judged by the research team or attending clinician to make participation unsafe or inappropriate
  • Inability or unwillingness to adhere to the 12-week ASK programme or study assessments
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    ASK Exercise Programme

    Participants assigned to this arm will receive the Aerobic, Strength, and Kegel exercise programme (ASK programme) in addition to standard postnatal care. The ASK programme is a 12-week home-based, app-guided exercise intervention supported by a wearable device. Participants will be asked to complete three exercise sessions per week, with each session lasting approximately 60 minutes. The programme includes aerobic exercise, strength training, and Kegel-based pelvic floor muscle training.

    Other: ASK Exercise Programme

  • No intervention
    Standard Postnatal Care

    Participants allocated to the control group will receive standard postnatal care, including routine postpartum follow-up and general health advice. They will not receive the ASK programme during the 12-week study period. They will complete the same baseline and post-intervention assessments as participants in the intervention group.

Interventions

  • OtherASK Exercise Programme

    The ASK Exercise Programme is a 12-week home-based, app-guided exercise intervention supported by a wearable device. Participants will be asked to complete three sessions per week, with each session lasting approximately 60 minutes. The programme includes aerobic exercise, strength training, and Kegel-based pelvic floor muscle training. The mobile app and wearable device will be used to support exercise delivery, self-monitoring, and adherence tracking.

05

What researchers measure

Primary outcomes

  1. Recruitment rate to the ASK Exercise Programme

    Recruitment rate will be calculated as the number of participants enrolled divided by the number of eligible participants approached. The outcome will be reported as a percentage of eligible participants approached.

    Time frame: From recruitment initiation to 12 weeks

  2. Retention rate in the ASK Exercise Programme

    Retention rate will be calculated as the number of enrolled participants who complete the 12-week follow-up assessment divided by the total number of enrolled participants. The outcome will be reported as a percentage of enrolled participants.

    Time frame: From baseline to 12 weeks

  3. Dropout rate from the ASK Exercise Programme

    Dropout rate will be calculated as the number of participants who withdraw or are lost to follow-up before the 12-week assessment divided by the total number of enrolled participants. The outcome will be reported as a percentage of enrolled participants.

    Time frame: From baseline to 12 weeks

  4. Assessment completion in the ASK Exercise Programme

    Assessment completion rate will be calculated as the number of completed planned study assessments divided by the total number of planned study assessments. The outcome will be reported as a percentage of planned study assessments.

    Time frame: From baseline to 12 weeks

  5. Participant satisfaction rate

    Participant satisfaction will be assessed using a study-specific acceptability questionnaire administered at 12 weeks. Satisfaction will be defined as reporting "satisfied" or "very satisfied" with the ASK Exercise Programme. The outcome will be reported as the percentage of participants who are satisfied or very satisfied.

    Time frame: At 12 weeks

  6. ASK session completion rate

    ASK session completion rate will be calculated as the number of prescribed ASK exercise sessions completed divided by the total number of prescribed ASK exercise sessions during the 12-week intervention period. Session completion will be assessed using app-recorded exercise completion data. The outcome will be reported as a percentage of prescribed ASK exercise sessions.

    Time frame: Throughout the 12-week intervention period

  7. Adverse events related to the ASK Exercise Programme

    Safety will be assessed as the number of participants who experience one or more adverse events related to the ASK Exercise Programme during the 12-week intervention period. Adverse events and exercise-related symptoms will be collected using participant symptom reports and study adverse event records. The outcome will be reported as the number of participants with adverse events related to the ASK Exercise Programme.

    Time frame: Throughout the 12-week intervention period

  8. Postpartum recovery score

    Postpartum recovery will be assessed using the Obstetric Quality of Recovery-10. The change from baseline to 12 weeks in the total Obstetric Quality of Recovery-10 score will be calculated. Total scores range from 0 to 100, with higher scores indicating better postpartum recovery.

    Time frame: Baseline and 12 weeks

  9. Postnatal depressive symptom score

    Postnatal depressive symptoms will be assessed using the Edinburgh Postnatal Depression Scale. The change from baseline to 12 weeks in the total Edinburgh Postnatal Depression Scale score will be calculated. Total scores range from 0 to 30, with higher scores indicating more severe depressive symptoms.

    Time frame: Baseline and 12 weeks

  10. Pelvic floor symptom distress score

    Pelvic floor symptom distress will be assessed using the Pelvic Floor Distress Inventory-20. The change from baseline to 12 weeks in the total Pelvic Floor Distress Inventory-20 score will be calculated. Total scores range from 0 to 300, with higher scores indicating greater pelvic floor symptom distress.

    Time frame: Baseline and 12 weeks

  11. Sleep quality score

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index. The change from baseline to 12 weeks in the global Pittsburgh Sleep Quality Index score will be calculated. Global scores range from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: Baseline and 12 weeks

  12. Breastfeeding self-efficacy score

    Breastfeeding self-efficacy will be assessed using the Breastfeeding Self-Efficacy Scale-Short Form. The change from baseline to 12 weeks in the total Breastfeeding Self-Efficacy Scale-Short Form score will be calculated. Total scores range from 14 to 70, with higher scores indicating greater breastfeeding self-efficacy.

    Time frame: Baseline and 12 weeks

  13. Health-related quality of life score

    Health-related quality of life will be assessed using the Short Form-12 Health Survey. The change from baseline to 12 weeks in the health-related quality of life score will be calculated. The outcome will be reported as a score on a scale, with higher scores indicating better health-related quality of life.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Body mass index

    Body mass index will be calculated as body weight in kilograms divided by height in meters squared. The change from baseline to 12 weeks in body mass index will be calculated. The outcome will be reported in kg/m².

    Time frame: Baseline and 12 weeks

  2. Waist-hip ratio

    Waist-hip ratio will be calculated as waist circumference divided by hip circumference. The change from baseline to 12 weeks in waist-hip ratio will be calculated. The outcome will be reported as a ratio.

    Time frame: Baseline and 12 weeks

  3. Resting heart rate

    Resting heart rate will be measured at baseline and 12 weeks. The change from baseline to 12 weeks in resting heart rate will be calculated. The outcome will be reported in beats per minute.

    Time frame: Baseline and 12 weeks

  4. Systolic blood pressure

    Systolic blood pressure will be measured at baseline and 12 weeks where available through home or routine clinical measurement. The change from baseline to 12 weeks in systolic blood pressure will be calculated. The outcome will be reported in mmHg.

    Time frame: Baseline and 12 weeks

  5. Diastolic blood pressure

    Diastolic blood pressure will be measured at baseline and 12 weeks where available through home or routine clinical measurement. The change from baseline to 12 weeks in diastolic blood pressure will be calculated. The outcome will be reported in mmHg.

    Time frame: Baseline and 12 weeks

  6. Fasting glucose concentration

    Fasting glucose concentration will be measured using fasting blood samples at baseline and 12 weeks. The change from baseline to 12 weeks in fasting glucose concentration will be calculated. The outcome will be reported in mmol/L.

    Time frame: Baseline and 12 weeks

  7. HbA1c

    HbA1c will be measured using blood samples at baseline and 12 weeks. The change from baseline to 12 weeks in HbA1c will be calculated. The outcome will be reported as a percentage.

    Time frame: Baseline and 12 weeks

  8. Triglyceride concentration

    Triglyceride concentration will be measured using fasting blood samples at baseline and 12 weeks. The change from baseline to 12 weeks in triglyceride concentration will be calculated. The outcome will be reported in mmol/L.

    Time frame: Baseline and 12 weeks

  9. Total cholesterol concentration

    Total cholesterol concentration will be measured using fasting blood samples at baseline and 12 weeks. The change from baseline to 12 weeks in total cholesterol concentration will be calculated. The outcome will be reported in mmol/L.

    Time frame: Baseline and 12 weeks

  10. High-density lipoprotein cholesterol concentration

    High-density lipoprotein cholesterol concentration will be measured using fasting blood samples at baseline and 12 weeks. The change from baseline to 12 weeks in high-density lipoprotein cholesterol concentration will be calculated. The outcome will be reported in mmol/L.

    Time frame: Baseline and 12 weeks

  11. Low-density lipoprotein cholesterol concentration

    Low-density lipoprotein cholesterol concentration will be measured using fasting blood samples at baseline and 12 weeks. The change from baseline to 12 weeks in low-density lipoprotein cholesterol concentration will be calculated. The outcome will be reported in mmol/L.

    Time frame: Baseline and 12 weeks

  12. Post-exercise recovery heart rate

    Cardiorespiratory fitness will be assessed using a 3-minute step test. Post-exercise recovery heart rate will be recorded after completion of the test. The change from baseline to 12 weeks in post-exercise recovery heart rate will be calculated. The outcome will be reported in beats per minute.

    Time frame: Baseline and 12 weeks

  13. Daily step count

    Daily step count will be recorded using wearable-derived activity data. Mean daily step count during the 12-week intervention period will be calculated. The outcome will be reported as steps per day.

    Time frame: Throughout the 12-week intervention period

  14. Daily active minutes

    Daily active minutes will be recorded using wearable-derived activity data. Mean daily active minutes during the 12-week intervention period will be calculated. The outcome will be reported as minutes per day.

    Time frame: Throughout the 12-week intervention period

  15. Exploratory gut microbiome profile

    Gut microbiome profiles will be assessed using stool samples collected at baseline and 12 weeks. Changes from baseline to 12 weeks in gut microbiome profiles will be explored, including microbial diversity and taxonomic composition, depending on sample availability and sequencing quality.

    Time frame: Baseline and 12 weeks

06

Study locations

1 site
  • The Department of Obstetrics and Gynaecology, The Chinese University Of Hong Kong
    Hong Kong, Hong Kong, Hong Kong
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07790289
Lead sponsor
Chinese University of Hong Kong
Responsible party
LAI KWAN LAM (Postdoctoral Fellow, Chinese University of Hong Kong) — Principal investigator
First posted
Aug 27, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Nov 30, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Sep 3, 2026

Study contacts

LAI KWAN LAM, PhD
Contact
laikwanlam@cuhk.edu.hk
+85235054267
Yao Wang, PhD
principal investigator · Chinese University of Hong Kong

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion